BPTH Bio Path Holdings Inc

Bio-Path Holdings Inc is a clinical & preclinical stage oncology focused antisense drug development company utilizing novel technology achieving systemic delivery for specific protein inhibition for any gene product that is over-expressed in disease.

$4.20  +0.15 (3.70%)
As of 12/06/2021 16:00:00 EST     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  01/11/2006
Outstanding shares:  7,160,164
Average volume:  121,256
Market cap:   $28,998,664
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    09057N300
ISIN:        US09057N3008
Sedol:      
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   1.02
PS ratio:   0.00
Return on equity:   -30.24%
Net income %:   0.00%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy